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Abstract 
Background: Light microscopy and antigen‑based rapid diagnostic tests are the primary diagnostic tools for detect‑
ing malaria, although being labour‑intensive and frequently challenged by lack of personnel’s experience and low lev‑
els of parasite density. The latter being especially important in non‑endemic settings. Novel molecular techniques aim 
to overcome this drawback. The objective of this study was to assess the diagnostic performance of the illumigene 
malaria  assay® (Meridian Bioscience) compared to microscopy, RDT and real‑time PCR. This loop‑mediated isothermal 
amplification (LAMP) assay is a qualitative in vitro diagnostic test for the direct detection of Plasmodium spp. DNA in 
human venous whole blood samples.
Methods: The illumigene assay was assessed on a retrospective panel of stored blood samples (n = 103) from 
returned travellers and external quality control samples (n = 12). Additionally the assay was prospectively assessed on 
30 fresh routine samples with a request for malaria diagnosis. The illumigene assay was compared to microscopy, RDT 
and Plasmodium species specific real‑time PCR.
Results: In the retrospective evaluation, the illumigene assay showed 100% agreement with the real‑time PCR, RDT 
and microscopy yielding a sensitivity and specificity of 100% (95% CI 95.1–100% and 89.7–100%, respectively). Seven 
samples from patients recently treated for Plasmodium falciparum infection that were RDT positive and microscopy 
negative yielded positive test results. The performance of the illumigene assay equals that of microscopy combined 
with RDT in the prospective panel with three false negative RDT results and one false negative microscopy result. 
Excellent concordance with PCR was observed. The limit of detection of the assay approached 0.5 parasites/µL for 
both P. falciparum and Plasmodium vivax.
Conclusion: In non‑endemic regions where the diagnostic process for malaria infections is questioned by lack of 
experience and low levels of parasite densities, the illumigene assay can be of value. Due to its high sensitivity, the 
LAMP assay may be considered as primary diagnostic test. The results of this study indicate that negative screen 
results do not need further confirmation. However, before implementation, this approach needs to be confirmed in 
larger, prospective studies. A shortcoming of this assay is that no species identification nor determination of parasite 
density are possible.
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Background
Imported malaria infections in non-endemic regions 
remain common due to increasing travel to endemic 
malaria areas and population movements [1–4]. Yearly, 
according to the World Health Organization (WHO) 
[5, 6], approximately 10,000 cases of imported malaria 
are reported, but the actual number may be as high as 
30,000. Rapid and accurate diagnosis of infections with 
species identification and determination of parasite den-
sity is essential to optimize treatment and reduce mortal-
ity [7–9]. However, diagnosis of imported cases can be 
challenging due to infrequent encounters [3, 10], leading 
to difficulties in diagnosis [11], misdiagnosis and delays 
in treatment.
Light microscopy and quality assured antigen-based 
rapid diagnostic tests (RDTs) are the primary diagnostic 
tools for confirmation and management of cases of sus-
pected clinical malaria in a non-endemic setting. Micro-
scopic examination of Giemsa-stained blood slides (thin 
and thick films) by trained and experienced staff has 
been the standard for malaria diagnosis for nearly a cen-
tury [1, 12]. However this technique is labour-intensive, 
time consuming and challenged by a high limit of detec-
tion (LoD). The latter, in ideal conditions estimated to be 
close to 50 parasites/µL, strongly depends on the quality 
of the slide and the training level of the microscopist [13]. 
Furthermore, personnel’s lack of practice and proficiency 
may account for delays and errors in diagnosis [11]. No 
alternative method has been accepted to replace this 
gold standard method yet [1, 12]. RDTs were introduced 
to overcome some of these drawbacks. Most RDTs cur-
rently used are based on immunochromatographic tech-
niques which detect histidine-rich protein 2 (HRP-2), 
a protein specific to Plasmodium falciparum, and pan-
Plasmodium parasite lactate dehydrogenase (pan-pLDH) 
or aldolase, enzymes common to all Plasmodium species 
[7]. Because RDTs are fast, easy to use, generally have 
good sensitivity for P. falciparum and have a relatively 
low cost, they are a valuable adjunct to (but not a replace-
ment for) microscopy for the diagnosis of malaria in the 
returned traveller [2, 6]. The sensitivity for P. falciparum 
is excellent at parasite densities > 100/µL (median 94.3%, 
range 77.4–98.1%), but significantly lower at densities 
below 100/µL (median 74.1%, range 9.1–88.5%). Of note, 
the sensitivity for non-falciparum species varies between 
different RDTs used (Plasmodium vivax: 66.0–88.0%; 
Plasmodium ovale: 5.5–86.7%; P. malariae: 21.4–45.2%), 
with a marked decline in sensitivity at parasite densities 
below 500/µL [6, 14].
Molecular techniques have drawn attention because 
they can overcome the most important disadvantages 
of RDTs such as decreasing sensitivity at low parasite 
density and limited capacity for identification of non-P. 
falciparum and mixed-species infections [6, 15–17]. 
Nucleic acid amplification techniques (NAATs) are sev-
eral orders of magnitude more sensitive than microscopy 
and RDTs [2]. Parasite densities in the case of P. falcipa-
rum in returned travellers may be below the RDT thresh-
old and below the (non-expert and expert) microscopy 
threshold [6, 18]. Previously published data suggested 
that approximately 10% of patients with P. falciparum 
infection presented with parasite density below 100/µL 
at the Institute of Tropical Medicine (ITM), Belgium [6]. 
Moreover, non-immune patients may develop clinical 
disease at very low parasite densities [18].
Polymerase chain reaction (PCR) techniques used to 
diagnose malaria infections include single-step, nested, 
multiplex and quantitative, conventional or real-time 
PCR formats. Other NAATs do not require thermal 
cyclers, the most common being loop-mediated isother-
mal amplification (LAMP) and nucleic acid sequence-
based amplification. The sensitivity of LAMP method is 
reported to approach that of nested PCR [19] and unlike 
PCR, samples for LAMP do not require extensive prepa-
ration [20].
The main objective of our study was to assess the 
diagnostic performance of the illumigene Malaria DNA 
Amplification  assay® (Meridian Bioscience, Inc., Cincin-
nati OH, USA), compared to microscopy, RDT and real-
time PCR for Plasmodium spp. detection.
Methods
Study design
In this study, the diagnostic performance of the illumi-
gene assay was assessed. In the retrospective part of the 
study, the assay was assessed against a selection of stored 
samples (n = 103) obtained from international travellers, 
collected from June 2015 to June 2016 and external qual-
ity controls (EQC) (n  =  12). The malaria RDT, micro-
scopic evaluation and real-time PCR [1] were carried out 
at the reference laboratory of the Institute of Tropical 
Medicine (ITM) Antwerp, Belgium. The illumigene assay 
was performed retrospectively at the clinical laboratory 
of the Ghent University Hospital (GUH).
Furthermore, the illumigene assay was prospectively 
assessed between July 2016 and September 2016 on 
30 samples obtained from patients suspected to have 
malaria infection at the clinical laboratory of the Ghent 
University Hospital (GUH). The malaria RDT, micro-
scopic evaluation and illumigene assay were completed at 
the GUH. Thereafter, all positive and discordant samples 
were sent to ITM for species identification and determi-
nation of parasite density. This study complied with the 
standards for the reporting of diagnostic accuracy studies 
(STARD).
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Clinical samples (retrospective and prospective)
A panel of stored EDTA-anticoagulated venous whole 
blood diagnostic samples (n  =  103) and EQC samples 
(n  =  12) was analysed. Blood samples were obtained 
from returned travellers who presented at the outpa-
tient clinic of the ITM or were submitted by diagnos-
tic laboratories for malaria confirmation to the Central 
Laboratory of Clinical Biology of ITM (the Belgian ref-
erence laboratory for Plasmodium, accredited according 
to ISO15189:2012). This panel contained 66 Plasmo-
dium positive samples covering the different Plasmo-
dium species (27 P. falciparum, 14 P. vivax, 13 P. ovale, 
12 P. malariae) as identified by real-time PCR (Cnops 
et al. [1]). Parasite densities were quantified microscopi-
cally on thick film by counting the asexual parasites (no 
gametocytes) per 200 white blood cells and converting 
this count to asexual parasites per microlitre. The para-
site densities of the samples varied between 1–372,117 
asexual parasites/µL (see Table 1 for more details). Also, 
30 Plasmodium negative specimens were included. These 
samples tested Plasmodium-negative through stand-
ard microscopy, RDT and real-time PCR. This negative 
panel included 5 samples to check for cross-reactivity 
(cfr. infra). Additionally 7 samples from patients who 
already received treatment for malaria infection were 
retrospectively tested (n  =  7/103). The EQC samples 
(from UK NEQAS) covered the 5 different species of 
Plasmodium (n  =  12, incl. 1 Plasmodium knowlesi) 
(Table 1).
All samples were stored at − 80 °C up to 1 year and had 
not been thawed before analysis. Performance of the illu-
migene assay on samples stored for more than 1 month 
up to 1 year at − 80 °C (i.e. maximal storage time accord-
ing to the manufacturer, Meridian Bioscience [21]) was 
evaluated on the first set of 20 Plasmodium positive 
samples.
The prospective panel consisted of thirty freshly drawn 
venous EDTA-anticoagulated whole blood samples con-
secutively collected from patients with clinical suspicion 
of malaria infection, and submitted to the laboratory of 
the GUH. These samples were stored for a maximum of 
1 week at 4  °C, meeting the specifications of the manu-
facturer. The illumigene assay was performed on de-iden-
tified residual samples by laboratory technicians blinded 
from RDT, microscopy and PCR test results.
Diagnostic test methods
The illumigene assay is a qualitative in  vitro diagnos-
tic LAMP test for the direct detection of Plasmodium 
spp. DNA in human venous EDTA whole blood samples 
Table 1 Shows malaria diagnosis for  115 retrospective samples by  the illumigene malaria assay in  comparison 
with standard microscopy, RDT and PCR
The retrospective panel consisted of 103 clinical samples (96 diagnostic samples and 7 samples from patients who already received treatment for malaria infection) 
and 12 external quality controls. These 7 samples from patients who already received treatment (115 − 7 = 108) were excluded from the calculation of both sensitivity 
and specificity. Parasite density as quantified by microscopy on blood smear
RDT, rapid diagnostic test; PCR, four-primer real-time PCR; Pf, Plasmodium falciparum; Pm, Plasmodium malariae; Po, Plasmodium ovale; Pv, Plasmodium vivax; Pk, 
Plasmodium knowlesi; n, number of samples; –*, the illumigene malaria assay does not distinguish between Plasmodium species
Reference method (RDT, microscopy, PCR) Illumigene malaria assay
Results (n) Range parasite density (asexual parasites/µL) Results (n) Performance
Total 108 108
 Positive  74  74 Sensitivity (%) (95% CI) 100% (95.1–100%)
 Negative  34  34 Specificity (%) (95% CI) 100% (89.7–100%)
Clinical samples 96
 Pf  27 (1–372,117)  –*
 Pv  14 (169–18,777)  –*
 Pm  13 (106–9244)  –*
 Po  12 (31–6461)  –*
 Mixed  0
 Negative  30
External quality controls 12
 Pf  1 5  –*
 Pv  1 5  –*
 Pm  2 5  –*
 Po  3 20  –*
 Pk  1 10,000
 Negative  4
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(50  µL). The assay targets a region of the Plasmodium 
genome that is conserved across P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi, i.e. a 214 bp sequence 
of the Plasmodium spp. mitochondrial DNA noncoding 
region. The assay does not distinguish between the differ-
ent Plasmodium species [21]. The price per test device (in 
euro, excl. VAT) is estimated 28€.
The assay uses a simple filtration workflow (SMP-
PREP™) to extract DNA from EDTA-anticoagulated 
whole blood, a procedure relying on chemical lysis which 
produces amplifiable DNA within 10  min [20, 22]. Fifty 
microlitres of the whole blood sample is added to a col-
lection tube containing 320 µL of illumigene lysis buffer 
and is thoroughly vortexed. After a 2 min incubation at 
room temperature, 50 µL of the lysate is added to a sim-
ple sample device with filter (SMP PREP IV) contain-
ing 900 µL of reaction buffer. After inverting five times, 
5–10 drops are gently squeezed from this device into a 
clean eppendorf tube. 50 µL of this eluate was added to 
both the test and control chamber of the illumigene test 
device [20, 22]. This test device consists of a TEST tube 
containing primers targeting the genus Plasmodium and 
a CONTROL tube with primers detecting the house-
keeping human gene acting as an amplification control. 
The LAMP assay was performed using the Illumipro-10™ 
Incubator/Reader, which is capable of testing maximal 10 
samples in a single run. The change in turbidity associ-
ated with LAMP amplification, due to the magnesium-
pyrophosphate build-up as a by-product, is visually 
detected by the reader and a qualitative result is deter-
mined (positive, negative or invalid) [20].
Each illumigene test device contains an internal control 
that controls for amplification inhibition, assay reagents, 
DNA preparation, and sample processing effectiveness 
[23]. It is however recommended by the manufacturer 
that the reactivity of each new lot and each new ship-
ment of illumigene test kits be verified on receipt and 
before use. External control tests should be performed 
in accordance with appropriate federal, state and local 
guidelines. Illumigene external control reagent is sup-
plied separately; alternatively, previously characterized 
clinical or contrived Plasmodium spp. positive blood 
samples can be used as an external positive control. A 
qualified negative human whole blood sample may be 
used as an external negative control. The test kit should 
not be used in patient testing if the external controls do 
not produce the correct results [23].
Reference method
The retrospective panel of clinical samples was tested 
at the reference laboratory of ITM using microscopy 
(Giemsa stained thin and thick film) and multiple 
RDTs: the SD FK60 Malaria Ag Pf/pan RDT-test (Alere, 
Waltham, Massachusetts, USA), which detects P. falcipa-
rum-specific HRP-2 and pan-pLDH [17]; the  CareStartTM 
Malaria pLDH 3 line test (AccessBio, Somerset, New Jer-
sey, USA), which detects P. falciparum-specific parasite 
lactate dehydrogenase (Pf-pLDH) and pan-pLDH [15]; 
and the SD FK80 Malaria Ag P.f/P.v test in case of P. vivax 
suspicion as it detects P. vivax-specific pLDH [24]. All 
retrospectively analysed samples (positive and negative) 
were confirmed with real-time PCR [1]. Analytical sen-
sitivity of this real-time PCR is 0.02 asexual parasites/µL 
for Pf/Pv, 0.004 for P. ovale and 0.006 for P. malariae [1].
The prospectively collected samples were compared 
with standard-of-care testing at the clinical labora-
tory of GUH. Routine testing consisted of RDT analysis 
 (BinaxNOW® malaria test, Alere), followed by micro-
scopic evaluation of Giemsa-stained thin and thick film 
by experienced staff. All positive and discordant samples 
were sent to reference laboratory of the ITM for species 
identification and assessment of parasite density. Nega-
tive samples with both microscopy and RDT were not 
sent to the reference laboratory for confirmation.
Statistical analysis
Sensitivity and specificity with 95% confidence intervals 
(CI) of the illumigene assay were determined using the 
real-time PCR as the reference test. All statistical analysis 
were performed with MedCalc software version 11.6.1.0 
(MedCalc Software, Ostend, Belgium).
Analytical sensitivity
The LoD of the illumigene assay is claimed by the manu-
facturer to be 2 parasites/µL for P. falciparum and 0.125/
µL for P. vivax [21]. In order to verify this LoD, blood 
samples from a patient with P. falciparum (parasite den-
sity = 6272/µL) and P. vivax (parasite density = 7285/µL) 
were diluted with uninfected blood from a healthy donor 
of the same blood group. Tenfold serial dilution was 
made to obtain a final parasite density of approximately 
0.5 parasite/µL. Dilution and analysis of samples were 
performed in duplicate.
Cross‑reactivity
To test the illumigene assay for cross-reactivity, 3 clinical 
samples with a PCR-confirmed infection with resp. Leish-
mania infantum, Trypanosoma brucei rhodesiense, and 
Schistosoma mansoni and 2 samples with a high concen-
tration of rheumatoid factor were tested.
Results
Diagnostic method comparison
The retrospective analysis of clinical samples (n =  103) 
and EQC samples (n = 12) showed complete agreement 
between the illumigene assay and the reference methods 
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(RDT, microscopy and PCR) (Table 1). No invalid LAMP 
results were observed. In a first set of 20 Plasmodium 
positive samples stored at −  80  °C for up to 1  year, all 
samples showed a positive result with the illumigene 
assay, justifying the evaluation of the assays’ performance 
on samples stored more than 1  month up to 1  year at 
− 80 °C. The illumigene assay demonstrated a sensitivity 
of 100% (95% CI 95.1–100%) and specificity of 100% (95% 
CI 89.7–100%) [samples from patients already treated for 
malaria infection not included (7/103)]. These additional 
tested samples from patients recently treated for P. falci-
parum infection (n = 7) also yielded positive test results 
and showed agreement with real-time PCR [1]. The 
median age of the patients was 36 (range 4–79) with 12 
(11.7%) < 15 years old. The male/female ratio was 72:31. 
The country of travel was known for 93 (90.3%) patients. 
Most returned from Africa (80.7%), followed by Asia 
(14.0%) and South-America (5.3%). The top three coun-
tries of destinations were Democratic Republic Congo 
(n  =  17), Cameroon (n  =  8), Côte d’Ivoire and Ghana 
(n = 6).
During the prospective validation, 30 consecutive 
samples were tested: 18 (60%) were identified as nega-
tive with the illumigene assay and 12 (40%) as positive 
(Table 2). The median age of the patients was 36 (range 
8–68) with 4 (11.7%)  ≤  15  years old. The male/female 
ratio was 20:10. The country of travel was known for 
29/30 (96.7%) of travellers. Most returned from Africa 
(58.6%), followed by Asia (34.5%) and South-America 
(6.9%). In 25/30 samples the status of malaria prophylaxis 
was known. Malaria prophylaxis was taken in 20% (5/25). 
No invalid results were observed. The negative illumigene 
assay results were in complete agreement with RDT and 
microscopy (n = 18, 100%), whereas the positive results 
showed excellent agreement with real-time PCR results 
for all samples tested (11/11, 100%). Species identifica-
tion with PCR showed 4 P. falciparum, 3 P. vivax and 2 
P. ovale single infections and 2 mixed infections (2 P. fal-
ciparum + P. ovale). Confirmation with PCR of 1 sample 
was not available (sample 12).
The illumigene assay showed 1 (1/30; 3.3%) discord-
ant result compared to microscopy (sample 12: positive 
illumigene test result, positive RDT result, but negative 
microscopic result). No left-over of whole blood was 
available for real-time PCR testing. PCR on a thin 
blood smear of this sample could not confirm the posi-
tive result of the illumigene assay. As compared with the 
RDT used (BinaxNOW), three additional positive sam-
ples (sample 9: 59 P. ovale parasites/µL; sample 10: 340 
P. vivax parasites/µL and sample 11: 415 P. falciparum 
parasites/µL) were detected with the illumigene assay 
(agreement in 27/30 samples, 90%). These three sam-
ples were confirmed positive with the reference method 
at ITM (microscopy, RDT and PCR). In contrast to the 
BinaxNOW, other RDTs used at the ITM showed posi-
tive results for these samples (sample 9: positive with 
Carestart panLDH and negative with SD; sample 10: pos-
itive with panLDH, Carestart panLDH and SD Pv; sam-
ple 11: positive with SD HRP-2 and Carestart PfLDH). 
Sample 11 was obtained from a patient, with a history 
of multiple (n  =  6) malaria infections, who traveled to 
Sierra Leone for 4  months without appropriate malaria 
prophylaxis and returned 3 days prior to sampling. In all 
3 cases the BinaxNOW RDT was repeated and showed 
consistently negative results. Furthermore, another sam-
ple was initially wrongly interpreted as RDT negative by a 
trained laboratory technician, but showed a faint positive 
result upon second assessment of the RDT afterwards. 
This sample revealed positive result with the illumigene 
assay (sample 8).
Analytical sensitivity
Positive test results were obtained for all concentrations 
tested with P. falciparum (i.e. 6272 parasites/µL, 1045/µL, 
104.5/µL, 10.5/µL, 2/µL, 1/µL and 0.5/µL) and P. vivax 
(i.e. 7285 parasites/µL, 10/µL, 2/µL, 1/µL and 0.5/µL).
Cross‑reactivity
No cross-reactivity was observed with rheumatoid fac-
tor or with the other blood parasites tested (Schistosoma, 
Leishmania, Trypanosoma). All 5 samples gave a negative 
test results on illumigene assay.
Discussion
The illumigene assay is designed to detect parasites of 
the genus Plasmodium and is developed as a qualita-
tive screening test for malaria infections. An advantage 
of LAMP assays in comparison to real-time PCR assays 
is the independence of expensive thermal cyclers. Only 
a compact incubator/reader is needed. Single testing or 
batch testing up to 10 samples at the same time is pos-
sible. The commercial illumigene assay offers a stand-
ardized method, which is easy to use, requiring minimal 
operator skills. The manufacturer claims a 100.0% sen-
sitivity and 89.3% specificity in comparison with expert 
microscopy [21]. Another study from the manufacturer 
claims a 99% sensitivity and 100% specificity compared 
with microscopy and PCR [22]. The data presented in 
this study support these findings and are in line with 
previous published data [25]. In contrast to Lucchi et al. 
who evaluated the assay in an endemic situation, this 
study focused on validating the illumigene assay in a 
non-endemic setting, where infections with low parasite 
densities are more frequent [26] and urgent diagnosis 
is essential to optimize treatment and reduce mortality. 
The illumigene LAMP assay results were compared to 
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microscopy, RDT and real-time PCR. Data on the perfor-
mance of a LAMP test in comparison to real-time PCR is 
rare.
In the retrospective experiment the illumigene assay 
showed 100% agreement with the real-time PCR method 
performed at the Belgian reference laboratory. Seven 
samples from patients, recently treated for P. falciparum 
infection, were also retrospectively tested on the platform 
and yielded, as expected, positive test results. As these 
samples still contained HRP-2 and P. falciparum-specific 
pLDH antigens they were also positive with RDT and 
real-time PCR, but no longer showed detectable parasite 
levels on expert microscopy. In the prospective panel, 
the performance of the illumigene assay equals that of 
RDT combined by microscopy, the current diagnostic 
approach in most laboratories in non-endemic regions. 
The illumigene assay detected three more positive sam-
ples than the BinaxNOW RDT alone and one additional 
positive sample compared to microscopy only in a patient 
with a history of multiple malaria infections. The posi-
tive LAMP result could not be confirmed with real-time 
PCR on thin blood smear, possibly due to inferior sample 
Table 2 Shows malaria diagnosis for  30 whole blood samples with  the illumigene malaria assay in  comparison 
with standard microscopy, RDT and PCR
Parasite density as quantified by microscopy on blood smear
RDT, rapid diagnostic test; PCR, four-primer real-time PCR; Pf, Plasmodium falciparum; Pm, Plasmodium malariae; Po, Plasmodium ovale; Pv, Plasmodium vivax; Pos, 
positive; Neg, negative. –, missing data; (#), negative result with real-time PCR performed on thin blood smear, possibly due to inferior sample quality; (*), difficult to 
interpret (weak positive result); /, triple negative results (i.e. negative with RDT, microscopy and illumigene malaria assay) were not sent to the ITM for confirmation 
with real-time PCR
Sample Illumigene RDT Microscopy PCR Parasite density (parasites/µL)
Result Species
1 Pos Pos Pos Pos Pf + Po 1,027,798
2 Pos Pos Pos Pos Pf 292,432
3 Pos Pos Pos Pos Pv 68,129
4 Pos Pos Pos Pos Pf 27,731
5 Pos Pos Pos Pos Pv 7285
6 Pos Pos Pos Pos Pf 5917
7 Pos Pos Pos Pos Pf + Po 98
8 Pos Pos (*) Pos Pos Po 1496
9 Pos Neg Pos Pos Po 59
10 Pos Neg Pos Pos Pv 340
11 Pos Neg Pos Pos Pf 415
12 Pos Pos Neg − (#) – –
13 Neg Neg Neg /
14 Neg Neg Neg /
15 Neg Neg Neg /
16 Neg Neg Neg /
17 Neg Neg Neg /
18 Neg Neg Neg /
19 Neg Neg Neg /
20 Neg Neg Neg /
21 Neg Neg Neg /
22 Neg Neg Neg /
23 Neg Neg Neg /
24 Neg Neg Neg /
25 Neg Neg Neg /
26 Neg Neg Neg /
27 Neg Neg Neg /
28 Neg Neg Neg /
29 Neg Neg Neg /
30 Neg Neg Neg /
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quality. The most plausible reason for the discordance 
with microscopy in this patient is prior treatment. Based 
on a dilution series, the LoD of the tested assay was at 
least 0.5 parasites/µL and agreed to the manufacturer’s 
claim for P. falciparum (i.e. 2 parasites/µL) [21]. In the 
panel of clinical samples 22 samples with a parasitaemia 
<  500/µL and 7 with densities <  100/µL were positive 
with the LAMP test. Molecular testing for Plasmodium 
DNA is clearly of value in cases where microscopy and/or 
RDT lack sensitivity [14].
The illumigene assay was designed for testing human 
venous whole blood samples (50 µL) with EDTA as pre-
servative [21, 23]. Simpler sample collection methods 
such as the use of a finger prick blood and filter papers 
may be preferable in field settings in resource-limited 
regions. However, the described evaluation was not 
designed to address the performance on capillary whole 
blood. This study was conducted in a non-endemic 
region without any resource limitations, therefore venous 
blood was relatively easily obtainable. Moreover, the col-
lection method of capillary blood can be unpractical, the 
sampling of 50–100 µL of whole blood sometimes cum-
bersome, and moreover the assay requires a sample anti-
coagulated with EDTA. Therefore, future studies aimed 
at evaluating this assay for detection of malaria in fresh 
capillary blood are warranted. Lucchi et al. [25] describe 
that they do not see any scientific reason why finger prick 
whole blood samples would not work with the LAMP 
assay described.
A shortcoming of the illumigene assay is that spe-
cies identification and determination of parasite density 
are not possible with this commercial LAMP assay. The 
development of species-specific primers for Plasmo-
dium species identification, is technically challenging 
and requires experience in PCR method development. 
Nevertheless, in-house designed malaria LAMP assays 
have been described capable of detecting both the Plas-
modium genus as well as the 5 different human infecting 
species [14, 27]. The need to identify the infecting species 
and the parasite density is, especially in non-endemic 
regions, important in order to provide the correct anti-
malarial therapy and in providing valuable information 
on the burden and relative distribution of malaria spe-
cies [25]. When using the illumigene LAMP assay, spe-
cies identification and determination of parasite density 
in positive samples through microscopy and/or real-time 
PCR remains necessary.
The results in this study suggest that the illumigene 
assay can be considered as an alternative first-line diag-
nostic tool instead of the combined approach of RDT 
and microscopy in non-endemic settings. The LAMP 
detected three Plasmodium infections that were negative 
with the BinaxNow RDT: one containing P. ovale (59 
parasites/µL), one containing P. vivax (340 parasites/
µL) and one containing P. falciparum (415 parasites/µL). 
This finding is in line with the compiled accuracy data for 
RDTs, i.e. variable sensitivity for the different species and 
variable performance dependent on the used RDT brand. 
In general most RDTs used, have high sensitivity for 
detecting P. falciparum but lower for other Plasmodium 
species [6, 12, 14]. Possible reasons for false-negative 
RDTs are most frequent low parasite density, and in case 
of P. falciparum prozone effect (rare) [28] and parasites 
with HRP2-gene deletion (rare) [29, 30].
Based upon the superior sensitivity and specificity 
of this assay compared with RDT and microscopy, the 
following novel approach could be considered in non-
endemic settings, particularly in situations with low posi-
tivity rates (Fig. 1): implementation of a molecular assay/
LAMP assay as a primary diagnostic test. Only positive 
results would require further diagnostic work-up with 
microscopy and real-time PCR (reference laboratory), 
in order to determine parasite density and species iden-
tification. Because of the high sensitivity of the illumi-
gene assay, confirmation of negative results by means of 
microscopy may not be necessary anymore. By using this 
approach, the majority of samples submitted to the labo-
ratory for suspected clinical malaria infection, no longer 
requires microscopic evaluation. This approach can be 
time-saving. However, due to low sample size results 
are inadequate to fully validate this approach and before 
implementation, the high sensitivity of this assay needs to 
be confirmed in larger, prospective and preferably multi-
center studies.
A minimum training for laboratory technicians was 
required to perform the illumigene assay. The sample 
preparation, incubation of samples and reading of test 
results is easy to perform as it does not require high-
level technical expertise. Hands-on time is limited to 
less than 10  min and results were available within 1  h. 
Results are shown as positive, negative or invalid and, 
therefore, require no subjective interpretation. All rea-
gents are provided in single-use packages and can be pre-
served for several months (i.e. 12 months, claim from the 
manufacturer, not tested in this study). Single testing or 
batch testing up to 10 samples at the same time is possi-
ble. This in contrast to real-time PCR where batch testing 
is required to save costs. During the validation no tech-
nical errors nor invalid test results were encountered. 
However, LAMP tests are currently more expensive than 
either microscopy and RDT [31]. The cost-effectiveness 
of the assay will depend on the number of samples and 
positivity rate, the experience of the microscopists and 
must be validated in every laboratory independently.
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Conclusion
In conclusion, the excellent performance of the illumi-
gene assay can lead to a fast, more accurate exclusion of 
clinical suspected malaria infection. These data provide 
additional support that this assay can be used as initial 
screening test before RDT and microscopy. Furthermore 
LAMP assays remain positive after treatment. Larger 
studies are required to confirm our results. Unfortu-
nately, this LAMP assay cannot identify the Plasmodium 
species nor determine parasite density. Therefore, expert 
microscopy remains the gold standard method for confir-
mation of malaria infection.
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